Buckle up! Falling Wedge pattern on Daily Ready to Rocket!Perfect close yesterday to bounce off support into a major move up! This is what we have been waiting for!
Notes:
-Stochastic: is sitting in a good spot: Neutral ( Not oversold or Over bought)
-On Balance Volume: Still trending up on the daily very strong sign, especially with the price decline in the short term, The OBV hints at strong momentum still.
-Falling Wedge: Setup is perfect. Its very clean and we are in a good spot!
-20 MA: to 20 moving average is a great support and sets up for a larger stronger bounce after a deep pullback like this.
-SSR in place today so Bulls can really have an advantage here!
-Pre Market: Off to a hot start!
Good Luck and Buy Buy Buy!!!!
Pharmaceuticals
NovaMax - a short term play?A comany that is capable of designing a vaccine for coronavirus.
It is difficult to say whether the price spike is due to the capability or their recent drug clinical trials succeeding.
Must Stay above the trend line Must stay above .35 or we go back down into the low .30's / high .20's.
Stop loss set at .35
Not taking any chances with Sabby here.
ENTRY! Akorn Inc. If you like the analysis, Please Like and Follow me for more.
View my previous post of Akorn inc. I evolved the bull flag slightly and found the bottom line the flag respects. An entry at current price would be ideal.
Nasdaq Healthcare: Closing on January 17thFriday's session presented a retracement on the 20 EMA Line, as predicted. I still believe in the continuation of the bullish trend. However, the bearish divergence needs to be monitored, since further price correction could occur.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Nasdaq Healthcare: Closing on January 16thToday's session generated a bearish divergence on CCI. I am still bullish, but always ready for a trend retracement on the 20 EMA Line.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Nasdaq Healthcare: Closing on January 15thIf you like this idea, don't forget to support it clicking the Like Button!
Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third candles (17:00 - 19:00)
The situation is also confirmed by RSI and CCI indicators.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Healthcare: Closing on January 14thGood session for the Nasdaq Healthcare Index, that closed the day with a 1.30% gain. Bullish sentiment is still driving trades. However next session could be characterized by a retracement around the basis of the Bollinger Bands indicator (orange crosses).
This is a daily analysis.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
LCI may start to climb after today's FDA approvalLannett stock has struggled lately due to opioid litigation and a weakening of its earnings forecast back in November. However, the company announced several product launches in December and early January, and today Lannett got FDA approval for, of all things, a cocaine-based anesthetic nasal spray. The stock has shown little positive reaction to any of this news, but that might change if analysts start to adjust their earnings forecasts to reflect the new product offerings. Despite its underwhelming reaction to the news today, I think Lannett may start to show momentum this week as investors digest the announcement from today.
Lannett has an attractive forward P/E of 6.84 and a history of beating analyst expectations on its earnings reports. Its last round of guidance was neutral, with increased administrative and sales costs offset by decreased tax burden and interest expense. Lannett should have enough cash on hand to cover its product launches thanks to a convertible notes offering last year. It has about $100 million in cash per its last earnings report, although with apparently $66 million in debt due toward the end of this year.
McKesson after-hours guidance raiseAfter-hours today, McKesson raised its FY EPS guidance to 14.60-14.80, about 2% above the consensus analyst estimate of 14.41. Its last round of guidance was disappointing, so this reflects a significant improvement in the company's fundamentals. Even though the guidance bump was only 2%, it could catalyze a much larger move in the stock price, which was already trading at a low forward P/E of about 10. Today's guidance implies a forward P/E of more like 9.7 based on today's closing price. McKesson has been in an uptrend anyway, so fortunately for me, I already owned some shares.
Alexion finally making movesI've been adding to my Alexion position since December 9, when I posted my previous idea on this stock. The wait is finally paying off, as the stock has surged higher in the past couple days. Alexion is getting unusually bullish call activity today, and the interest is more than justified at this forward P/E of less than 10 and PEG ratio of less than 1.
Alexion next reports earnings on February 3, and there are reasons to think it may top Wall Street expectations, including a history of earnings beats and a Zack's ESP of 2.07%. The consensus EPS estimate this quarter is $2.53, but the most accurate estimate is $2.58.
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud).
I was waiting for today's opening to confirm a bullish position.
Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase.
I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic.
The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline.
Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult.
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Great opportunity coming up Teva is going to hit a major resistance line causing a bounce back making two very high-profit scenarios that can be taken advantage of. I would recommend a entry of $8.50 or higher and an exit with your own judgment and stop losses.
$AMRN to $17 for re-accumulationAmarin ready for a dive to at least $17 for institutional re-accumulation before violating thru resistance and making new highs to $30 this year. Temporary short which I will re-evaluate and flip after liquidity is taken from support areas.
NASDAQ:AMRN
Insider confidence in Adial Pharmaceuticals bodes wellAs Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A. Bankole also just acquired over 3,000 shares, perhaps as part of his own compensation plan. If AD04 succeeds in clinical trials, it could be a very profitable drug.
Exelixis made a long-awaited trend line crossI've been waiting on this trend line cross in Exelixis for quite a while now. It's been getting lots of analyst upgrades, and the valuation has been looking better and better. I actually bought some of this in anticipation of the break yesterday, so I'm in the green today. Exelixis's valuation got a 99/100 score from S&P Capital IQ. It has an attractive P/E of 8. There was an insider sale by the senior vice president on October 10, which is a little worrying, but the stock held its price over the last few days, and this trend line breach means the stock should be bullish for the near future.
Things are looking up for Johnson & JohnsonJohnson & Johnson beat Wall Street's earnings expectations yesterday and raised its full-year guidance. The company has also been steadily settling opioid lawsuits, with another settlement rumored to be in the works soon. JNJ is rated highly undervalued by S&P Capital IQ, and its post-earnings run looks to be the slow, steady kind rather than a big spike. That's what I like to see. I've picked up a little JNJ and plan to ride it up to at least the 139.50 resistance level. I'm considering a long-term hold, although the political risk makes me cautious about this sector going into an election year.
SNOA: $4.35 | Sold Out Shares & Under Valuedwith new products addressing aesthetic industry should recover when volume
starts to kick in
Alexion Pharmaceuticals is outrageously undervaluedAfter noticing some call buying activity in Alexion Pharmaceuticals today, I gave the stock a look.
Analysts like Alexion. It has an 8.8/10 analyst summary score and an average price target of about $146.50 (versus the current price of about $113). S&P Global Intelligence rates it 85/100 for quality and 87/100 for financial health. Its growth stability earns a score of 62/100, which is great for a pharmaceutical company. Alexion has a nice, diverse portfolio of products that gives it some resiliency against changes in the demand for any one particular drug.
But the most attractive thing about Alexion stock is its valuation. The forward P/E of about 10 is very low for a stock with such extraordinary earnings growth. Analyst forecasts for Alexion's earnings have risen something like 25% over the last two years, but the share price has fallen over the same period. Moreover, Alexion has beaten estimates for every single one of the last 8 quarters. S&P Global Intelligence rates Alexion's valuation 97/100 (extremely undervalued)! Today's headline from DJ Realtime News is, "Elliott Looks Forward to Continuing Dialogue With Alexion in Effort to Close Gap Between Current Share Price and Fundamental Value."
Go to YouTube and check out my "Wall Street Petting Zoo" video titled "How to Determine the Fair Value of a Stock." There I describe how to use the Zacks "Price and Consensus" chart to determine the fair value of a stock. By this standard, Alexion is conservatively worth $175 per share.
ABBV remains a strong investment even after its recent runAbbvie has been surging lately after a bullish trend line break, but it remains undervalued at the current price. The analyst summary score for Abbvie is 9.6/10, and the average analyst price target is $92 per share. Personally, I think Abbvie's strong earnings forecast and 5.5% dividend yield justifies $100 per share. Call volume in Abbvie is very bullish today after its cancer drug Imbruvica beat a rival cancer drug in a clinical trial.
$MNK Go timeAscending Wedge Reversal.
Volume is there and ready to go.
Generic opioid manufacturers have been beaten down recently over fear of a copious monetary fine, but MNK has an established diverse profile.
Do NOT miss this stock when it runs.
Break above $4.15 and were off
Long Term Target: $12.90
Will Glaxosmithkline break out?Pressure is building and a breakout could be imminent.
It's taken 6 years from May 2013 where the high was 1816
Needs substantive news to make the push over the 1750s
